Hepion Pharmaceuticals, Inc.
Company Information
Industry Pharmaceutical Preparations
SIC Code 2834
Entity Type operating
SEC Category Non-accelerated filerSmaller reporting company
State of Incorporation DE
Business Address 399 THORNALL STREET, EDISON, NJ, 08837
Mailing Address 399 THORNALL STREET, EDISON, NJ, 08837
Phone 732-902-4000
Fiscal Year End 1231
EIN 462783806
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 8-K Current report of material events | January 15, 2026 | View on SEC |
| 10-Q Quarterly financial report | November 12, 2025 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | August 14, 2025 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | August 14, 2025 | View on SEC |
| 10-Q Quarterly financial report | August 14, 2025 | View on SEC |
| 8-K Current report of material events | June 30, 2025 | View on SEC |
| 8-K Current report of material events | June 12, 2025 | View on SEC |
| 8-K Current report of material events | June 9, 2025 | View on SEC |
| 8-K Current report of material events | May 30, 2025 | View on SEC |
| 10-Q Quarterly financial report | May 19, 2025 | View on SEC |
Material Events
8-K Leadership Change January 15, 2026
High Impact
- Hepion Pharmaceuticals appointed Dr. Kaouthar Lbiati as new CEO to drive strategic growth.
- Dr. Lbiati brings over 20 years of experience in drug development, clinical operations, and strategic leadership, especially in liver disease and oncology.
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.